Tumor-stroma ratio is a prognostic factor for survival in hepatocellular carcinoma patients after liver resection or transplantation

Surgery (United States)

Volumn 158, Issue 1, 2015, Pages 142-150

  Lv, Zhen ^a,b   Cai, Xianlei ^a,c   Weng, Xiaoyu ^a,b   Xiao, Heng ^a,b   Du, Chengli ^a,b   Cheng, Jun ^a,b   Zhou, Lin ^b   Xie, Haiyang ^b,c   Sun, Ke ^a   Wu, Jian ^a,b,c   Zheng, Shusen ^a,b,c  

^a ZHEJIANG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b Collaborative Innovation Center of Diagnosis and Treatment of Infectious Diseases ^*  (China)

^c Key Laboratory of Combined Multi Organ Transplantation Ministry of Public   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA FETOPROTEIN;

ADULT; AGED; ALPHA FETOPROTEIN BLOOD LEVEL; ARTICLE; CANCER GRADING; CANCER SIZE; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; FEMALE; FOLLOW UP; HUMAN; LIVER CELL CARCINOMA; LIVER RESECTION; LIVER TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; PRIORITY JOURNAL; RECURRENCE FREE SURVIVAL; STROMA; TUMOR STROMA RATIO; VERY ELDERLY; CARCINOMA, HEPATOCELLULAR; CELLS; EXTRACELLULAR SPACE; LIVER; LIVER NEOPLASMS; MORTALITY; PATHOLOGY; PROGNOSIS; RETROSPECTIVE STUDY; SURVIVAL;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, HEPATOCELLULAR; CELLS; EXTRACELLULAR SPACE; FEMALE; HEPATECTOMY; HUMANS; LIVER; LIVER NEOPLASMS; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; PROGNOSIS; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS;

EID: 84938701794     PISSN: 00396060     EISSN: 15327361     Source Type: Journal    
DOI: 10.1016/j.surg.2015.02.013     Document Type: Article

References (25)

1. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBO-CAN 2008. Int J Cancer 2010;127:2893-917.
2. Forner A, Llovet JM, Bruix J. Hepatocellular carcinoma. Lancet 2012;379:1245-55.
3. Yuen MF, Hou JL, Chutaputti A. Hepatocellular carcinoma in the Asia pacific region. J Gastroenterol Hepatol 2009;24:346-53.
4. Blechacz B, Mishra L. Hepatocellular carcinoma biology. Recent Results Cancer Res 2013;190:1-20.
5. El-Serag HB, Davila JA, Petersen NJ, McGlynn KA. The continuing increase in the incidence of hepatocellular carcinoma in the United States: an update. Ann Intern Med 2003;139:817-23.
6. El-Serag HB. Hepatocellular carcinoma. N Engl J Med 2011;365:1118-27.
7. Pietras K, Ostman A. Hallmarks of cancer: interactions with the tumor stroma. Exp Cell Res 2010;316:1324-31.
8. Mazzaferro V, Regalia E, Doci R, Andreola S, Pulvirenti A, Bozzetti F, et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med 1996;334:693-9.
9. Yao FY, Ferrell L, Bass NM, Watson JJ, Bacchetti P, Venook A, et al. Liver transplantation for hepatocellular carcinoma: expansion of the tumor size limits does not adversely impact survival. Hepatology 2001;33:1394-403.
10. Clavien PA, Lesurtel M, Bossuyt PM, Gores GJ, Langer B, Perrier A. Recommendations for liver transplantation for hepatocellular carcinoma: an international consensus conference report. Lancet Oncol 2012;13:e11-22.
11. Zheng SS, Xu X, Wu J, Chen J, Wang WL, Zhang M, et al. Liver transplantation for hepatocellular carcinoma: Hang-zhou experiences. Transplantation 2008;85:1726-32.
12. Mesker WE, Junggeburt JM, Szuhai K, De Heer P, Morreau H, Tanke HJ, et al. The carcinoma-stromal ratio of colon carci-nomaisanindependentfactor for survival comparedtolymph node status and tumor stage. Cell Oncol 2007;29:387-98.
13. Wang K, Ma W, Wang J, Yu L, Zhang X, Wang Z, et al. Tumor-stroma ratio is an independent predictor for survival in esophageal squamous cell carcinoma. J Thorac Oncol 2012;7:1457-61.
14. Liu J, Liu J, Li J, Chen Y, Guan X, Wu X, et al. Tumor-stroma ratio is an independent predictor for survival in early cervical carcinoma. Gynecol Oncol 2014;132:81-6.
15. Dekker TJ, Van De Velde CJ, Van Pelt GW, Kroep JR, Julien JP, Smit VT, et al. Prognostic significance of the tumor-stroma ratio: validation study in node-negative premenopausal breast cancer patients from the EORTC perioperative chemotherapy (POP) trial (10854). Breast Cancer Res Treat 2013;139:371-9.
16. Seshadri RM, Besur S, Niemeyer DJ, Templin M, McKillop IH, Swan RZ, et al. Survival analysis of patients with stage I and II hepatocellular carcinoma after a liver transplantation or liver resection. HPB (Oxford) 2014;16:1102-9.
17. Courrech SE, Smit VT, Van Velthuysen ML, Spitzer-Naaykens JM, Wouters MW, Mesker WE, et al. Reproducibility and validation of tumour stroma ratio scoringonoesophageal adeno-carcinoma biopsies. Eur J Cancer 2011;47:375-82.
18. De Wever O, Mareel M. Role of tissue stroma in cancer cell invasion. J Pathol 2003;200:429-47.
19. Liotta LA, Kohn EC. The microenvironment of the tumour-host interface. Nature 2001;411:375-9.
20. Gupta DK, Singh N, Sahu DK. TGF-beta mediated crosstalk between malignant hepatocyte and tumor microenvironment in hepatocellular carcinoma. Cancer Growth Metastasis 2014;7:1-8.
21. Erez N, Truitt M, Olson P, Arron ST, Hanahan D. Cancer-associated fibroblasts are activated in incipient neoplasia to orchestrate tumor-promoting inflammation in an NF-kappaB-dependent manner. Cancer Cell 2010;17:135-47.
22. Calon A, Tauriello DV, Batlle E. TGF-beta in CAF-mediated tumor growth and metastasis. Semin Cancer Biol 2014;25:15-22.
23. Reichl P, Haider C, Grubinger M, Mikulits W. TGF-beta in epithelial to mesenchymal transition and metastasis of liver carcinoma. Curr Pharm Des 2012;18:4135-47.
24. Eiro N, Vizoso FJ. Inflammation and cancer. World J Gastrointest Surg 2012;4:62-72.
25. Allavena P, Sica A, Garlanda C, Mantovani A. The Yin-Yang of tumor-associated macrophages in neoplastic progression and immune surveillance. Immunol Rev 2008;222:155-61.